Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | PALB2 mutant |
| Therapy | Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin |
| Indication/Tumor Type | pancreatic adenocarcinoma |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| PALB2 mutant | pancreatic adenocarcinoma | sensitive | Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin | Guideline | Actionable | FOLFIRINOX is included in guidelines as a preferred neoadjuvant therapy for pancreatic adenocarcinoma patients harboring PALB2 mutations with resectable/borderline resectable disease and as a preferred first-line therapy for patients with locally advanced or metastatic disease with good performance status (ECOG 0 -1) (NCCN.org). | detail... |
| PubMed Id | Reference Title | Details |
|---|---|---|
| NCCN.org | Full reference... |